The end users of fiducial markers include hospitals & outpatient facilities, independent radiotherapy centers, and cancer research centers. As FM placement around tumors is generally a noncritical procedure, it is typically performed in outpatient settings seven days before radiotherapy. This has ensured a sustained demand for the services of such facilities. In addition, the growing adoption of EBRT procedures (that utilize FMs for tumor localization) and the development & modernization of healthcare facilities are supporting the growth of this segment.

The flexible & semi-rigid ureteroscopy market is expected to reach USD 1,054.1 million by 2023 from USD 809.6 million in 2018, at a CAGR of 5.4%. The high incidence of urolithiasis across the globe is a major factor driving the growth of this market. The rapidly increasing geriatric population, technological advancements in devices, and improving hospital infrastructures are the other major factors that are expected to support the growth of the flexible & semi-rigid ureteroscopy market in the coming years.

The fiducial markers market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to be the fastest-growing region owing to improvements in healthcare infrastructure and supportive government initiatives. In addition, the growing incidence of cancer and the rising acceptance of radiotherapy procedures are propelling market growth.

Viral inactivation is important and mandatory step in the manufacturing process of biological products to remove or inactivate potential contaminant viruses. These biological products are used for the treatment and diagnostic purposes in humans. As the disease burden in the world is increasing the demand for the medicines is increasing hence the production of biologicals, injectables etc., is on a rise.

Major factors driving the growth of this market include a high incidence of gynecological diseases, increasing awareness of gynecological diseases, and rising government investments for providing advanced healthcare facilities & services. In addition, emerging Asian markets have opened an array of opportunities for players in this market. However, the increasing preference for robotic surgeries may restrain the growth of this market.

Viral inactivation testing is necessary by regulatory authorities for investigational new drug (IND) submission and is mainly critical in process development for biologicals including tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, and vaccine and therapeutics.

Biobanking Market plays an integral role in advancing biomedical and translational research, through the collection and preservation of biological samples, such as blood, tissues, and nucleic acids, which are then made available for use in research to discover disease-relevant biomarkers; this is further used for diagnosis, prognosis, and predicting drug responses.

Viral inactivation is important and mandatory step in the manufacturing process of biological products to remove or inactivate potential contaminant viruses. These biological products are used for the treatment and diagnostic purposes in humans. As the disease burden in the world is increasing the demand for the medicines is increasing hence the production of biologicals, injectables etc., is on a rise.

[153 Pages Report] The global bone growth stimulator market is estimated to reach USD 1.41 billion by 2022 from 1.03 billion at a CAGR of 5.4% during the forecast period. The growing patient preference for non-invasive and minimally invasive surgical treatments, increasing target patient population, and procedural benefits offered by bone stimulation devices in bone fracture treatments are some key factors propelling the growth of this market. However, limited medical reimbursement for bone stimulation products and high treatment costs associated with BMP and PRP products may hinder the growth of this market during the forecast period.

Metabolomics plays a vital role in the fields of toxicity testing, biomarker development, drug discovery, and clinical diagnostics. Factors such as the growing demand for personalized medicine, increasing pharmaceutical and biotech R&D expenditure, and rising necessity for toxicology testing are driving the growth of the metabolomics market. Additionally, the potential for metabolomics to move beyond basic research and into the field of diagnostics, by integrating with other omics technologies such as proteomics and transcriptomics, is also supporting the growth of the metabolomics market during the forecast period.

Continuous technological advancements in automation solutions, increasing government financial support for medical automation, rising labour costs, and growing need for reproducibility and accuracy are key factors fuelling the growth of the medical automation market. Increasing demand for automation in laboratories and pharmacies and high potential for early detection and treatment of diseases due to automation are some other prime factors offering growth opportunities for players in the medical automation market.

Factors such as growing population and rapid urbanization across the globe, increased affordability and preference for animal protein, increased adoption of genetic services and advanced genetic practices such as artificial insemination and embryo transfer for larger-scale production and quality breeds, and growing focus on identifying superior breeds are likely to boost the growth of the market.

In this report, the animal genetic market has been segmented by product & services, and region. Based on animal genetic product, the live animal segment accounted for the largest share.

[241 Pages Report] The animal genetic market is projected to reach USD 5.8 billion by 2023 from USD 4.2 billion in 2018, at a CAGR of 6.5 % during the forecast period. Factors such as growing population and rapid urbanization across the globe, increased affordability and preference for animal protein, increased adoption of genetic services and advanced genetic practices such as artificial insemination and embryo transfer for larger-scale production and quality breeds, and growing focus on identifying superior breeds are likely to boost the growth of the market.

Viral inactivation testing is necessary by regulatory authorities for investigational new drug (IND) submission and is mainly critical in process development for biologicals including tissue and tissue products, stem cell products, cellular and gene therapy products, blood and blood products, and vaccine and therapeutics. The major drivers for the market are rapid growth in pharmaceutical and biotechnology industries and strong trend of R&D investments in life sciences industry.

The Research Report analyzes and studies the price variation in medical robots of varied types (surgical/rehabilitation/non-invasive radiosurgery/hospital & pharmacy), selection criteria of adopting medical robots from an end-user perspective, buying a cycle, price wars, and cost-benefits offered by the robots based on existing research studies. According to the new market research report “Medical Robots Transforming Healthcare:…

The end users of fiducial markers include hospitals & outpatient facilities, independent radiotherapy centers, and cancer research centers. As FM placement around tumors is generally a noncritical procedure, it is typically performed in outpatient settings seven days before radiotherapy. This has ensured a sustained demand for the services of such facilities. In addition, the growing adoption of EBRT procedures (that utilize FMs for tumor localization) and the development & modernization of healthcare facilities are supporting the growth of this segment.

[241 Pages Report] The animal genetic market is projected to reach USD 5.8 billion by 2023 from USD 4.2 billion in 2018, at a CAGR of 6.5 % during the forecast period. Factors such as growing population and rapid urbanization across the globe, increased affordability and preference for animal protein, increased adoption of genetic services and advanced genetic practices such as artificial insemination and embryo transfer for larger-scale production and quality breeds, and growing focus on identifying superior breeds are likely to boost the growth of the market.